Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Janumet vs Glimepiride in Type 2 Diabetes Mellitus
NCT00993187Phase 4
Key facts
- Status
- Completed
- Start
- May 2010
- Primary completion
- Oct 2013
- Sponsor
- Merck & Co.
- Conditions
- type 2 diabetes mellitus (T2DM)
01
Overview
Phase 4, randomised, double-blind trial of sitagliptin + metformin in type 2 diabetes mellitus (T2DM), sponsored by Merck & Co. Primary endpoint: Change From Baseline in Hemoglobin A1C at 30 weeks. Started May 2010; status: completed.
02
Design
- Study design
- RandomizedDouble-blind
03
Who it enrols
Patients with type 2 diabetes mellitus with HbA1c between 6.5% and 9.5% depending on prior AHA status, excluding those with HIV, obesity, or significant liver/cardiac disease.
04
Endpoints
Primary
Change From Baseline in Hemoglobin A1C
Beyond the preview
Go deeper on NCT00993187.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00993187.